The investigational therapy gantenerumab significantly lowered levels of established biomarkers in a rare, inherited form of early-onset Alzheimer’s disease, despite failing to slow cognitive decline or memory loss in symptomatic and asymptomatic patients, according to data from a Phase 2/3 clinical trial. Based on these results, enrolled patients may choose to continue, or start, on gantenerumab as part of an open-label extension study. Another possible treatment evaluated in the trial, solanezumab, failed to either prevent cognitive decline…
You must be logged in to read/download the full post.
The post Gantenerumab Lowers Key Protein Levels in Early-onset Disease Trial appeared first on BioNewsFeeds.